Study: NCT00895882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaniprevir (MK7009)
Description: vaniprevir 300 mg soft gel capsules twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaniprevir (MK7009)
Description: vaniprevir 300 mg soft gel capsules twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: vaniprevir (MK7009)
Description: vaniprevir 600 mg soft gel capsules twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: vaniprevir (MK7009)
Description: vaniprevir 600 mg soft gel capsules twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: vaniprevir (MK7009)
Description: vaniprevir 600 mg soft gel capsules twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Pegylated Interferon (peg-IFN) alfa-2a
Description: Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Pegylated Interferon (peg-IFN) alfa-2a
Description: Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Pegylated Interferon (peg-IFN) alfa-2a
Description: Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Pegylated Interferon (peg-IFN) alfa-2a
Description: Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Pegylated Interferon (peg-IFN) alfa-2a
Description: Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Pegylated Interferon (peg-IFN) alfa-2a
Description: Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Ribavirin
Description: Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Ribavirin
Description: Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Ribavirin
Description: Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Ribavirin
Description: Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Ribavirin
Description: Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Ribavirin
Description: Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo to vaniprevir
Description: Placebo to vaniprevir soft gel capsules twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo to vaniprevir
Description: Placebo to vaniprevir soft gel capsules twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo to vaniprevir
Description: Placebo to vaniprevir soft gel capsules twice daily.